Thursday, October 15, 2026

Coffee Futures Over 3% Down In The Last 10 Sessions

Coffee Futures Over 3% Down In The Last 10 Sessions

(VIANEWS) - Coffee (KC) has been up by 3.75% for the last 10 sessions. At 05:52 EST on Wednesday, 24 July, Coffee (KC) is $236.15.

Volume

Today's last reported volume for Coffee is 2867, 86.48% below its average volume of 21206.15.

Volatility

Coffee's last week, last month's, and last quarter's current intraday variation average was 0.14%, 0.23%, and 2.95%, respectively.

Coffee's highest amplitude of average volatility was 2.18% (last week), 1.89% (last month), and 2.95% (last quarter), respectively.

News about

  • Crude oil struggles to recover footing on Tuesday despite API barrel count contraction. According to FXStreet on Tuesday, 23 July, "With hopes of a broad recovery in Chinese fuel demand going up in smoke, markets are finding little reason to keep supporting Crude Oil prices as geopolitical tensions in the Middle East continue to sizzle with no foreseeable impact after months of concerns about a possible crimp in global Crude Oil production.", "Daily candlesticks paint a notable bearish picture, with US Crude Oil prices threatening to backslide to early June's bottom bids near $72.50 and price action descending almost unimpeded below the 200-day EMA at $79.23."
  • According to FXStreet on Monday, 22 July, "This, in turn, is seen lending some support to the USD-denominated commodities, including Crude Oil prices.", "This, along with China's economic woes, should keep a lid on any meaningful upside for Crude Oil prices."

More news about Coffee (KC).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com